Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Julie S. Larsen"'
Autor:
Dingwei Ye, Katherine B. Bevans, Andrea J. Pereira de Santana Gomes, Sabine Brookman-May, Byung Ha Chung, Simon Chowdhury, Suneel Mundle, Álvaro Juárez, Ke Zhang, Kim N. Chi, Mustafa Ozguroglu, Anders Bjartell, Sharon Anne McCarthy, Julie S. Larsen, Neeraj Agarwal, Weili Sun, Robert Given, Nibedita Bandyopadhyay, Hirotsugu Uemura, Axel S. Merseburger
Publikováno v:
Journal of Clinical Oncology. 39:2294-2303
PURPOSE The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sen
Autor:
Eric J. Small, Fred Saad, Julie S. Larsen, Neeraj Agarwal, Suneel Mundle, Simon Chowdhury, Matthew R. Smith, Julie N. Graff, Stéphane Oudard, Gang Li, Angela Lopez-Gitlitz, Kim N. Chi, Sharon Anne McCarthy
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The phase 3 TITAN and SPARTAN studies demonstrated improved outcomes with the addition of apalutamide (APA) to androgen deprivation therapy (ADT); outcomes included prolo...
Autor:
Axel S. Merseburger, Suneel Mundle, Angela Lopez-Gitlitz, Anil Londhe, Anders Bjartell, Andrea J. Pereira de Santana Gomes, Álvaro Juárez Soto, Hirotsugu Uemura, Kim N. Chi, Robert Given, Simon Chowdhury, Julie S. Larsen, Mustafa Ozguroglu, Sharon Anne McCarthy, Neeraj Agarwal, Dingwei Ye, Byung Ha Chung
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:TITAN showed that apalutamide (APA) + androgen deprivation therapy (ADT) improves overall survival (OS), radiographic progression-free survival (rPFS), and time to prosta...
Autor:
Yishai Ofran, Julie S. Larsen, Steven Knapper, Marion Subklewe, Gail J. Roboz, Indrajeet Singh, Michael Heuser, Ho Jin Shin, Agnieszka Wierzbowska, Claude Eric Bulabois, Mehmet Ali Özcan, Liang Xiu, Jorge E. Cortes, Daniel A. Pollyea, Gert J. Ossenkoppele, Sergio Giralt, Uwe Platzbecker, Pau Montesinos, Stefan Deneberg, Fei Huang, Cristina Papayannidis, Andrew H. Wei, Su-Peng Yeh, Hartmut Döhner, Vadim Doronin
Publikováno v:
Leukemia
Montesinos, P, Roboz, G J, Bulabois, C E, Subklewe, M, Platzbecker, U, Ofran, Y, Papayannidis, C, Wierzbowska, A, Shin, H J, Doronin, V, Deneberg, S, Yeh, S P, Ozcan, M A, Knapper, S, Cortes, J, Pollyea, D A, Ossenkoppele, G, Giralt, S, Döhner, H, Heuser, M, Xiu, L, Singh, I, Huang, F, Larsen, J S & Wei, A H 2021, ' Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy : results from a multicenter, randomized, phase 2/3 study ', Leukemia, vol. 35, no. 1, pp. 62-74 . https://doi.org/10.1038/s41375-020-0773-5
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Leukemia, 35(1), 62-74. Nature Publishing Group
Montesinos, P, Roboz, G J, Bulabois, C E, Subklewe, M, Platzbecker, U, Ofran, Y, Papayannidis, C, Wierzbowska, A, Shin, H J, Doronin, V, Deneberg, S, Yeh, S P, Ozcan, M A, Knapper, S, Cortes, J, Pollyea, D A, Ossenkoppele, G, Giralt, S, Döhner, H, Heuser, M, Xiu, L, Singh, I, Huang, F, Larsen, J S & Wei, A H 2021, ' Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy : results from a multicenter, randomized, phase 2/3 study ', Leukemia, vol. 35, no. 1, pp. 62-74 . https://doi.org/10.1038/s41375-020-0773-5
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Leukemia, 35(1), 62-74. Nature Publishing Group
Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in combination with decitabine in elderly patients with acute myeloid leukemia (AML) not eligible for intensive chemotherapy. A multicenter, phase 2/3 study was initiated to det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50ffc80d49fb9dc9e35dcb946c3ebdf7
https://europepmc.org/articles/PMC7787975/
https://europepmc.org/articles/PMC7787975/
Autor:
Kris Deprince, Tomoyoshi Hatayama, Junya Aoyama, Hirotsugu Uemura, Kazuyoshi Iijima, Hiroji Uemura, Gaku Arai, Kim N. Chi, Jinhui Li, Julie S. Larsen, Sharon Anne McCarthy, Angela Lopez-Gitlitz, Koji Fujii, Hiroyoshi Suzuki, Kazuo Nishimura
Publikováno v:
International journal of urology : official journal of the Japanese Urological AssociationReferences. 28(3)
Objective To evaluate the efficacy and safety of apalutamide + androgen deprivation therapy versus androgen deprivation therapy alone in Japanese patients with metastatic castration-sensitive prostate cancer from the phase 3, randomized, global TITAN
Autor:
Anders Bjartell, Weili Sun, Suneel Mundle, Spyros Triantos, Katherine B. Bevans, Ke Zhang, Mustafa Ozguroglu, Byung Ha Chung, Simon Chowdhury, Kim N. Chi, Sharon Anne McCarthy, Andrea J. Pereira de Santana Gomes, Robert Given, Axel S. Merseburger, Julie S. Larsen, Nibedita Bandyopadhyay, Hirotsugu Uemura, Neeraj Agarwal, Álvaro Juárez Soto, Dingwei Ye
Publikováno v:
Journal of Clinical Oncology. 39:11-11
11 Background: TITAN evaluated APA or PBO added to ADT in pts with mCSPC. Pts with high- and low-volume disease, prior docetaxel, prior treatment for localized disease, and prior ADT (≤ 6 mos) were eligible. At the first interim analysis, with 22.7
Autor:
Shibu Thomas, Felix Y. Feng, Neeraj Agarwal, Gerhardt Attard, Deborah Ricci, Simon Chowdhury, Alexander W. Wyatt, Angela Lopez-Gitlitz, Kim N. Chi, Julie S. Larsen, Michael Gormley, Dong Shen, Branko Miladinovic
Publikováno v:
Cancer Research. 80:776-776
Background: In TITAN, APA improved radiographic progression-free survival (rPFS), overall survival (OS), and second progression-free survival (PFS2) vs placebo (PBO) in patients (pts) with mCSPC receiving ADT. We determined the presence of genomic an
Autor:
Alexander W. Wyatt, Angela Lopez-Gitlitz, Michael Gormley, Gerhardt Attard, Shibu Thomas, Clemente Aguilar-Bonavides, Kim N. Chi, Deborah Ricci, Felix Y. Feng, Neeraj Agarwal, Simon Chowdhury, Julie S. Larsen, Elai Davicioni
Publikováno v:
Journal of Clinical Oncology. 38:5535-5535
5535 Background: In TITAN, addition of APA to ADT improved radiographic progression-free survival (rPFS) and overall survival (OS) versus PBO plus ADT in patients (pts) with mCSPC. In this post hoc analysis, we performed transcriptome-wide profiling
Autor:
Jinhui Li, Ke Zhang, Andrea J. Pereira de Santana Gomes, Margaret K. Yu, Anders Bjartell, Sharon Anne McCarthy, Kim N. Chi, Simon Chowdhury, Kris Deprince, V. Naini, Mustafa Ozguroglu, Robert Given, Hirotsugu Uemura, Julie S. Larsen, Neeraj Agarwal, Axel S. Merseburger, Dingwei Ye, Álvaro Juárez Soto, Shinta Cheng, Byung Ha Chung
Publikováno v:
Journal of Clinical Oncology. 37:5006-5006
5006 Background: TITAN was designed to determine whether APA, a selective next-generation androgen receptor inhibitor, plus ADT improves radiographic progression-free survival (rPFS) and overall survival (OS) compared with PBO plus ADT in pts with mC
Autor:
Kathryn V. Blake, Julie S. Larsen
Publikováno v:
Journal of Pharmacy Practice. 14:228-252
Allergic rhinitis and sinusitis are chronic conditions of the airway and cause significant morbidity. Both can require pharmacotherapy with nonprescription products to relieve symptoms or with prescription products to treat the underlying pathophysio